Skip to Main content Skip to Navigation
Master Thesis

Traitement des progressions tumorales dans le cancer du poumon muté EGFR : à propos d'une cohorte de patients métastatiques suivis à l'Institut Bergonié

Abstract : Lung cancer is the leading cause of cancer death in France. In above 75% of cases, disease is too advanced to permit curative treatments. Adenocarcinomas are the principal histologic type, with above 10% of epidermal growth factor (EGFR) mutations. These mutations lead to constitutive activation of this receptor. Tumors presenting EGFR mutations have a dramatically response rate to tyrosine kinase inhibitors (TKI). Responses occur during 10 to 12 months in median. After this period, all patients improve relapses because of emergence of tumor resistance. Several therapeutics strategies are proposed but there are not therapeutics standards for treatment of these resistances. The aim of this study was to analyze clinical and molecular characteristics of relapses of 69 patients treated at Bergonie Institute (Bordeaux) and to evaluate therapeutics strategies used. We have shown that oligometastatic patients might benefit of local treatments, with TKI continuation. For others relapses, a biopsy must be realized. Molecule assessment of these biopsies can guide treatments. Slow and asymptomatic progressions are often due to EGFR-dependant progressions, and can be treated with TKI continuation or chemotherapy and rechallenge. EGFR-independent relapses lead to rapid or symptomatic progressions and must be treated with chemotherapies. New treatments like new generation TKI or immunotherapies will change these strategies and might be considered in future trials.
Document type :
Master Thesis
Complete list of metadata

Cited literature [161 references]  Display  Hide  Download

https://dumas.ccsd.cnrs.fr/dumas-01245774
Contributor : Bu Carreire Université de Bordeaux <>
Submitted on : Thursday, December 17, 2015 - 4:10:11 PM
Last modification on : Friday, October 23, 2020 - 5:02:47 PM
Long-term archiving on: : Saturday, April 29, 2017 - 6:44:12 PM

Identifiers

  • HAL Id : dumas-01245774, version 1

Collections

Citation

Charlotte Domblides. Traitement des progressions tumorales dans le cancer du poumon muté EGFR : à propos d'une cohorte de patients métastatiques suivis à l'Institut Bergonié. Médecine humaine et pathologie. 2015. ⟨dumas-01245774⟩

Share

Metrics

Record views

336

Files downloads

1817